The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017
An evaluation of circulating cytokines milieu in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 311s Year: 2002
Angiogenic activity of sera from tuberculosis and sarcoidosis patients in relation to IL-12 and TNFα serum level Source: Annual Congress 2003 - Genetics and immunobiology of tuberculosis Year: 2003
Correlation of serum TNF-α, IL-4 and sIL-2R levels with radiologic and clinical manifestations in active pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 339s Year: 2003
Serum cytokine and antiviral antibody in the clinical course of sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003
Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease? Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Relationship between macrophage inflammatory protein-3β(MIP-3β) levels and clinical course of sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002
TNF-alpha, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
Serum interleukin 18 as a monitoring marker of long clinical course of pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 711s Year: 2004
Type 2 cytokines and biomarkers in asthma patient sera show coordinated expression and identify patient subsets Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases Year: 2019
Can intermediate monocytes predict response to infliximab therapy in sarcoidosis? Source: Eur Respir J 2016; 48: 1242-1245 Year: 2016
Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis? Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004
Serum concentration of cytokines before and during treatment in patients with active tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 10s Year: 2002
Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011
Prognostic role of CCL18 serum concentrations in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007
There are no correlations between the level of serum antichlamidia antibodies and clinical course of sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 539s Year: 2006
Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021
The diagnostic value of serum soluble CD 14 and IL-10 levels in newly diagnosed pulmonary tuberculosis patients and the relationship with disease extensity Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
The relationship between level of C-reactive protein in blood serum and clinical manifestations of the disease in patients with pulmonary tuberculosis Source: Annual Congress 2010 - Tuberculosis: metabolic insights Year: 2010
Serum biomarkers in SSc-ILD: association with presence, severity and prognosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019